Stocks and Investing
Stocks and Investing
Mon, September 24, 2018
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Fri, September 21, 2018
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Derek Archila Maintained (VNDA) at Buy with Increased Target to $29 on, Sep 21st, 2018
Derek Archila of Oppenheimer, Maintained "Vanda Pharmaceuticals Inc." (VNDA) at Buy with Increased Target from $27 to $29 on, Sep 21st, 2018.
Derek has made no other calls on VNDA in the last 4 months.
There are 2 other peers that have a rating on VNDA. Out of the 2 peers that are also analyzing VNDA, 1 agrees with Derek's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Charles Duncan of "Cantor Fitzgerald" Initiated at Hold and Held Target at $26 on, Thursday, August 23rd, 2018
This is the rating of the analyst that currently disagrees with Derek
- Joel Beatty of "Citigroup" Initiated at Strong Buy on, Wednesday, May 23rd, 2018